Business · 29/02/2024Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for EPI-SENSE GUIDED COAGULATION SYSTEM
Summary
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the EPI-SENSE GUIDED COAGULATION SYSTEM, a medical device, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).
Original source language: Federal Register — Food and Drug AdministrationOpen original release →